1. Home
  2. ARHS vs KALV Comparison

ARHS vs KALV Comparison

Compare ARHS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arhaus Inc.

ARHS

Arhaus Inc.

HOLD

Current Price

$6.36

Market Cap

956.8M

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.79

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARHS
KALV
Founded
1986
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
956.8M
1.0B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
ARHS
KALV
Price
$6.36
$26.79
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$10.78
$32.60
AVG Volume (30 Days)
1.4M
5.4M
Earning Date
05-07-2026
07-09-2026
Dividend Yield
4.78%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$1,379,222,000.00
$50,000,000.00
Revenue This Year
$7.23
$185.42
Revenue Next Year
$7.10
$59.23
P/E Ratio
$318.50
N/A
Revenue Growth
8.51
495.66
52 Week Low
$5.57
$9.83
52 Week High
$12.97
$26.85

Technical Indicators

Market Signals
Indicator
ARHS
KALV
Relative Strength Index (RSI) 44.54 74.68
Support Level $6.17 $14.25
Resistance Level $7.62 $26.85
Average True Range (ATR) 0.35 0.07
MACD -0.02 -0.22
Stochastic Oscillator 36.65 71.05

Price Performance

Historical Comparison
ARHS
KALV

About ARHS Arhaus Inc.

Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: